欢迎访问《现代生物医学进展》编辑部！

目的：探讨肼苯哒嗪对疝修补术后患者慢性疼痛发生率的影响。方法：选择单侧腹股沟疝患者48人，随机分为实验组（T组）和对照组（C 组）各24 例，在术前3 天至术后4 天共7 天内接受药物或安慰剂治疗。其中T 组每日两次，每次10mg 肼苯哒嗪，C 组同样方式给予安慰剂。测量患者术后4天内的平均动脉压（MAP）、心率（HR）、NRS急性疼痛评分以及术后3月、6月S-LANSS 慢性疼痛评分。结果：T 组患者术后MAP明显低于C 组（P<0.05），HR 两组相比无差异（P>0.05）；两组患者术后急性疼痛程度相比无统计学差别（P>0.05）；T组患者在术后3月和6月慢性疼痛发生率明显低于C 组（P<0.05）。结论：常规剂量肼苯哒嗪可以用于术后患者，对疝修补术后急性疼痛无影响，但可以明显降低术后慢性疼痛的发生率。

英文摘要:

Objective: To explore the role of hydralazine in prevention of postoperative chronic pain. Methods: 48 patients with herniorrhaphy were randomly divided into Test group (T group, n=24) and Control group (C group, n=24). The patients in T group were treated with 10 mg hydralazine BID, and the patients in C group was administered with placebo in the same manner. The MAP, HR, NRS score were measured during the first four days after operation, and S-LANSS scores were reported by every available patient at 3 and 6 months postoperatively. Results: The MAP level of T group patients was significantly lower than that of C group （P<0.05）; HR in the two groups has no signicant difference（P>0.05）.There was no significant differences of NRS scores in the two groups（P>0.05）. The incidences of postoperative chronic pain was obviously lower in T group than those in C group（P<0.05）. Conclusions: Hydralazine can obviously decrease the incidence of postoperative chronic pain rather than the acute pain in patients after herniorrhaphy.

View Full Text View/Add Comment Download reader